Can High Bilirubin Cause Death in Adults?

Severely elevated bilirubin in adults is strongly linked to life-threatening outcomes, though the danger usually comes from the underlying condition driving bilirubin up rather than the pigment acting alone. In acute liver failure, sepsis, biliary obstruction, and massive hemolysis, bilirubin levels climb as the body loses its ability to process and excrete this breakdown product of old red blood cells. At extreme concentrations, bilirubin itself can also inflict direct damage on the brain, kidneys, and other organs. Understanding when and why bilirubin turns deadly matters because it is one of the most widely measured blood values in hospitals, and a sharply rising number on a lab report can signal that a patient’s condition is deteriorating fast.

What Bilirubin Is and Why It Rises

Bilirubin is the yellow-orange pigment released when your body breaks down hemoglobin from aging red blood cells. The liver processes this raw (unconjugated) bilirubin, attaches it to a sugar molecule to make it water-soluble (conjugated bilirubin), and ships it into bile for excretion through the intestines. A normal total bilirubin level sits below about 1.2 mg/dL. Jaundice, the visible yellowing of skin and eyes, typically appears once levels climb above 2.5 to 3 mg/dL.

Bilirubin can rise for broadly three reasons: overproduction (when red blood cells are being destroyed faster than normal), impaired processing (when the liver is too damaged or overwhelmed to conjugate it), or blocked excretion (when bile cannot drain from the liver into the intestine). Each of these paths can produce dangerously high levels, and the specific path matters for both treatment and prognosis. A bilirubin of 20 mg/dL from a gallstone blocking the bile duct tells a very different clinical story than the same number from acute liver failure, even though both are alarming.

Liver Failure and Decompensated Cirrhosis

The most common scenario where high bilirubin and death converge in adults is advanced liver disease. When the liver fails acutely or when chronic cirrhosis decompensates, the organ loses its capacity to process bilirubin, and levels can soar into the teens, twenties, or higher. In these patients, bilirubin is not just a bystander; it is one of the strongest single predictors of short-term death.

A study of patients with acute-on-chronic liver failure found that total bilirubin at admission was independently associated with dying within one week. Both the conjugated and unconjugated fractions carried prognostic weight, and on receiver-operating-characteristic analysis, conjugated and total bilirubin were the best short-term mortality predictors among the variables tested.¹ This is why bilirubin features prominently in clinical scoring systems used to prioritize patients for liver transplant. In the widely used Model for End-Stage Liver Disease (MELD) score, bilirubin is one of just three laboratory values that determine how urgently someone needs a new liver.

A prospective study of patients with acute decompensated cirrhosis found that the ratio of bilirubin to albumin separated survivors from non-survivors strikingly well. Among patients in the highest quartile of that ratio, only about 57% were alive at 180 days, compared with roughly 96% in the lowest quartile.² Bilirubin is also one of the factors driving the SOFA score and other ICU-based tools used to gauge organ failure in cirrhotic patients admitted to intensive care, where mortality rates for those with three or more organs failing can reach 90%.³

Sepsis and Critical Illness

High bilirubin during sepsis is a red flag that the body’s infection response is overwhelming the liver. Jaundice in a septic patient typically signals either direct liver injury from the infection, impaired bile flow due to systemic inflammation, or a combination. Regardless of the cause, the numbers paint a grim picture.

A large population-based study found that sepsis patients whose total bilirubin reached 5 mg/dL or higher faced about 1.6 times the risk of dying within a year compared with septic patients whose bilirubin stayed below that threshold.⁴ Elevated bilirubin in sepsis also raises the odds of developing acute respiratory distress syndrome (ARDS), a potentially fatal complication in which the lungs fill with fluid. For each 1 mg/dL increase in admission bilirubin, the risk of ARDS rose by about 7%, and among those who did develop ARDS, 28-day mortality climbed roughly 20% per additional mg/dL.⁵

What makes this association particularly dangerous is when high bilirubin shows up alongside a falling platelet count. A study of critically ill patients found that early high bilirubin combined with low platelets carried more than two and a half times the odds of dying within 30 days, whereas high bilirubin alone, without the platelet drop, did not significantly increase 30-day mortality after adjusting for other factors.⁶ This combination hints at a broader collapse of organ function rather than isolated liver trouble, and it is a signal clinicians take seriously in the ICU.

Biliary Obstruction and Cholangitis

When something physically blocks the bile duct, whether a gallstone, a tumor, or scar tissue, conjugated bilirubin backs up into the bloodstream and levels rise steeply. If bacteria then infect the stagnant bile, the condition escalates into acute cholangitis, a medical emergency that can progress to septic shock within hours.

A multicenter study of 382 patients with acute cholangitis severe enough to require intensive care found an overall in-hospital mortality rate of 29%. Bilirubin at admission was independently associated with death: for every increase of roughly 3 mg/dL, the odds of dying rose by about 26%. Obstruction caused by cancer rather than gallstones, and the presence of complications like organ failure, further worsened the outlook.⁷ A separate retrospective analysis of 140 cases of severe cholangitis in an ICU found a nearly identical mortality rate of 28%, with 90% of those deaths attributable to cholangitis-related sepsis.⁸

The treatment for obstructive jaundice is to relieve the blockage, usually by passing a scope into the bile duct (endoscopic retrograde cholangiopancreatography, or ERCP) to remove stones or place a stent. When drainage is achieved quickly and antibiotics control the infection, outcomes improve dramatically. The danger lies in delayed intervention, because each hour of ongoing obstruction with active infection gives sepsis more time to cascade into multi-organ failure.

Drug-Induced Liver Injury and Hy’s Law

Medications can occasionally cause liver damage severe enough to push bilirubin to dangerous levels. In the world of drug safety, one of the most ominous signals is known as Hy’s Law, named after the late hepatologist Hyman Zimmerman, who observed that drug-induced liver injury producing both elevated liver enzymes and jaundice carries a fatality rate of roughly 10% or higher. The concept has been refined with modern data.

An analysis using the Drug-Induced Liver Injury Network database confirmed that patients meeting criteria for a hepatocellular pattern of injury (where the liver cells themselves are damaged, rather than bile flow being impaired) had a mortality rate of about 11%, compared with 2% for those whose injury pattern was primarily cholestatic or mixed.⁹ This distinction matters because jaundice in drug-induced liver injury is not uniformly deadly. When bilirubin rises because bile flow is impaired (cholestatic injury), the prognosis is better than when it rises because liver cells are dying en masse. Hy’s Law applies specifically to the hepatocellular scenario, and it is one reason drug trials are halted when certain combinations of liver enzyme elevations and bilirubin rises appear in study participants.

Hemolytic Crises

When red blood cells are destroyed at an extraordinary rate, the flood of released hemoglobin can overwhelm the liver’s processing capacity, sending unconjugated bilirubin levels far beyond normal. This happens in severe autoimmune hemolytic anemia, transfusion reactions, certain infections, and in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are exposed to a trigger like infection or specific drugs.

A report of five G6PD-deficient patients who developed severe intravascular hemolysis during acute viral hepatitis illustrates how bad it can get. Bilirubin levels reached extreme heights, three of the five developed acute kidney failure, and one patient with both hepatic coma and kidney failure died.¹⁰ The surviving four recovered over weeks to months, but the case underscores that the combination of hemolysis plus liver damage is especially perilous because both bilirubin production and bilirubin clearance are compromised simultaneously.

Kidney Damage From Extreme Bilirubin

One of the less widely known ways bilirubin contributes to death is through direct injury to the kidneys. Bile cast nephropathy, sometimes called cholemic nephropathy, occurs when high levels of bilirubin and bile acids spill into the kidney tubules and form casts that physically obstruct them. It is most commonly seen in patients who already have severe liver disease, creating a vicious cycle: the failing liver drives bilirubin up, the bilirubin damages the kidneys, and the resulting kidney failure makes the patient even harder to stabilize.

A systematic review of reported cases found that nearly 90% of patients with bile cast nephropathy had acute kidney injury, with average creatinine levels nearly four times normal at the time of diagnosis.¹¹ Kidney function improved with treatment in many cases, but the added burden of renal failure in someone who is already critically ill from liver disease sharply raises the risk of death. Techniques like therapeutic plasma exchange and molecular adsorbent recirculating systems (MARS) can physically remove bilirubin from the blood and have shown promise in recovering kidney function in these patients, though the evidence comes largely from case series rather than large trials.¹²

Kernicterus in Adults

Kernicterus, the condition where unconjugated bilirubin crosses into the brain and damages specific regions, is overwhelmingly a disease of newborns. Their blood-brain barrier is immature, and the bilirubin-processing enzyme is not yet fully active. Adults are largely protected because their blood-brain barrier is more robust and their liver has much greater conjugation capacity. But “largely” is not “completely.”

High concentrations of unconjugated bilirubin can cause nervous system damage in adults, though it is considered a rare condition.¹³ The documented cases tend to involve patients who had both sky-high unconjugated bilirubin and a compromised blood-brain barrier due to another illness. One reported case involved a 43-year-old woman with severe liver damage from hepatitis, whose unconjugated bilirubin reached extreme levels after extracorporeal treatment depleted clotting factors and caused hemorrhages. She died in hepatic coma, and autopsy confirmed kernicterus with the characteristic staining of the hippocampus, subthalamic nuclei, and cerebellar structures.¹⁴

At the cellular level, research has shown that unconjugated bilirubin disrupts mitochondrial membranes in neurons, triggering a cascade of events that leads to cell death.¹⁵ This membrane damage is not unique to newborn brains; adult neurons are vulnerable too when exposed to high enough concentrations. Research on isolated mitochondria has demonstrated that unconjugated bilirubin causes membrane permeabilization and release of cytochrome c, a key step in the cellular self-destruct sequence, though protective agents like ursodeoxycholic acid can partially block this process.¹⁶

Bilirubin After Major Surgery

Patients who undergo major liver surgery face a particular risk from rising bilirubin in the days that follow. The liver needs a minimum amount of functional tissue to keep up with its hundreds of metabolic jobs, and when a surgeon removes a large portion, the remaining liver can be temporarily or permanently overwhelmed.

A study of patients after major liver resection found that a total bilirubin level of 3 mg/dL or higher on the third day after surgery was a powerful early warning sign. Patients who hit that threshold had a 90-day mortality rate of about 16%, compared with roughly 2% in those who stayed below it. Major complications were also far more common, affecting about 46% of the high-bilirubin group versus 18% of the low-bilirubin group.¹⁷ The clinical takeaway is that a bilirubin reading that would be considered only mildly elevated in a normal context becomes a serious alarm in a post-surgical patient, because it signals the remaining liver may not be up to the task.

Genetic Conditions That Keep Bilirubin High for Life

Some adults live with chronically elevated bilirubin due to inherited enzyme deficiencies. The most common is Gilbert syndrome, which affects roughly 5 to 10% of Western populations and produces mild, harmless jaundice during fasting or illness. Gilbert syndrome does not threaten life.

At the other extreme is Crigler-Najjar syndrome type 1, in which the enzyme responsible for conjugating bilirubin is completely absent. Without treatment, unconjugated bilirubin reaches levels that cause brain damage in the first weeks of life. Patients who survive into adulthood do so because of daily phototherapy sessions lasting 10 to 12 hours, in which blue light converts bilirubin in the skin into forms that can be excreted without liver conjugation. Even with consistent phototherapy, bilirubin control tends to worsen with age as the body grows and the skin-to-volume ratio shrinks.¹⁸ Liver transplant is currently the only definitive cure, though gene therapy approaches are in development.

Crigler-Najjar type 2 is less severe, with partial enzyme activity and bilirubin levels that respond to the drug phenobarbital, which stimulates the remaining enzyme. These patients face a lower but not zero risk of bilirubin encephalopathy, particularly during intercurrent illness or surgery when bilirubin can spike unpredictably.

The Flip Side: When Low-Normal Bilirubin Is the Problem

The relationship between bilirubin and death is not a simple straight line pointing upward. At mildly elevated levels, bilirubin acts as an antioxidant, and population studies have consistently found that people with slightly higher bilirubin within the normal range tend to have lower rates of heart disease. A large general-population study found that very low bilirubin levels were associated with higher all-cause mortality, while levels in a mildly elevated range appeared protective for cardiovascular death. The association between bilirubin and cardiovascular mortality was non-linear: a range of roughly 0.7 to 1.1 mg/dL was associated with higher cardiovascular risk, while above that range the protective effect plateaued.¹⁹

This helps explain why Gilbert syndrome, which keeps bilirubin mildly elevated, has been associated with reduced cardiovascular risk in several studies. It also adds context for interpreting bilirubin results: a level of 1.5 or 2 mg/dL in an otherwise healthy person is not a cause for alarm and may even be mildly beneficial. The danger zone lies much higher, and it almost always arrives in the company of serious underlying disease rather than as an isolated laboratory quirk.

Research on bilirubin’s cellular effects supports this dual personality. At low concentrations, bilirubin reduces oxidative stress and can even protect cells from damage caused by toxins like cigarette smoke extract. But at higher concentrations, the same molecule turns cytotoxic, reducing cell viability in a dose-dependent manner.²⁰ The threshold between helpful and harmful depends on the cell type and context, but the broad principle holds: a little bilirubin is good, a lot is not.